AIM
IBB icon

Advantage Investment Management’s iShares Biotechnology ETF IBB Stock Holding History

Advantage Investment Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$34K Sell
342
-90
-21% -$9.42K 0.03% 411
2019
Q2 		$47K Sell
432
-210
-33% -$22.3K 0.04% 356
2019
Q1 		$72K Hold
642
– – 0.06% 278
2018
Q4 		$62K Hold
642
– – 0.05% 306
2018
Q3 		$78K Sell
642
-93
-13% -$11K 0.05% 318
2018
Q2 		$81K Hold
735
– – 0.06% 287
2018
Q1 		$78K Sell
735
-66
-8% -$7.32K 0.03% 315
2017
Q4 		$86K Hold
801
– – 0.03% 316
2017
Q3 		$89K Hold
801
– – 0.03% 277
2017
Q2 		$83K Sell
801
-66
-8% -$6.5K 0.03% 265
2017
Q1 		$85K Sell
867
-1,539
-64% -$147K 0.03% 249
2016
Q4 		$213K Buy
2,406
+1,641
+215% +$149K 0.08% 142
2016
Q3 		$74K Sell
765
-90
-11% -$8.56K 0.03% 262
2016
Q2 		$73K Sell
855
-2,400
-74% -$215K 0.03% 284
2016
Q1 		$283K Buy
3,255
+2,475
+317% +$221K 0.12% 107
2015
Q4 		$88K Sell
780
-60
-7% -$6.51K 0.05% 252
2015
Q3 		$85K Sell
840
-15
-2% -$1.8K 0.05% 240
2015
Q2 		$105K Buy
855
+192
+29% +$23K 0.05% 234
2015
Q1 		$76K Buy
663
+438
+195% +$48.3K 0.04% 278
2014
Q4 		$23K Buy
+225
New +$21.9K 0.02% 404

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Advantage Investment Management's IBB Position: Q3 2019 in Review

Advantage Investment Management reduced its iShares Biotechnology ETF (IBB) stake by 21% in Q3 2019, selling an estimated $9.42K and leaving 342 shares worth $34K. The position accounts for 0.03% of the portfolio, ranked #411.

Advantage Investment Management first reported a position in IBB in Q4 2014 and has held it in 20 quarters since. The position peaked at $283K in Q1 2016. 597 funds tracked by Wall St. Rank hold IBB as of Q3 2019.

  • Advantage Investment Management held 342 shares of iShares Biotechnology ETF worth $34K as of Q3 2019.
  • Advantage Investment Management sold 90 iShares Biotechnology ETF shares in Q3 2019, an estimated $9.42K.
  • iShares Biotechnology ETF made up 0.03% of Advantage Investment Management's portfolio in Q3 2019, its #411 holding.
  • Advantage Investment Management first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 20 quarters since.
  • Advantage Investment Management's iShares Biotechnology ETF position peaked at $283K in Q1 2016.
  • 597 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.